Related references
Note: Only part of the references are listed.A Patient with Leiden V Mutation, Multiple Sclerosis, Psoriasis, and Sicca Syndrome: Could Celecoxib and Fingolimod Adversely Affect the Heart?
G. Cocco
CARDIOVASCULAR TOXICOLOGY (2012)
Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence
G. Giovannoni et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
The changing face of multiple sclerosis clinical trial populations
Bernard M. J. Uitdehaag et al.
CURRENT MEDICAL RESEARCH AND OPINION (2011)
Delayed fingolimod-associated asystole
Patricio S. Espinosa et al.
MULTIPLE SCLEROSIS JOURNAL (2011)
Future clinical challenges in multiple sclerosis Relevance to sphingosine 1-phosphate receptor modulator therapy
Reinhard Hohlfeld et al.
NEUROLOGY (2011)
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Ludwig Kappos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Jeffrey A. Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Sphingosine 1-phosphate receptors in health and disease: Mechanistic insights from gene deletion studies and reverse pharmacology
Volker Brinkmann
PHARMACOLOGY & THERAPEUTICS (2007)
Oral fingolimod (FTY720) for relapsing multiple sclerosis
Ludwig Kappos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Share Paper
